OncoResponse

OncoResponse today announced the results of the Phase 1 trial of OR502, our novel, humanized anti-LILRB2 antibody. A Late-Breaking Poster Presentation discussing the results will occur at the Society for Immunotherapy of Cancer (SITC) 2024 conference on November 9th. The full poster is now available on our website. "We are pleased that OR502 has demonstrated an excellent safety profile and compelling early efficacy signals," said Clifford Stocks, Chief Executive Officer of OncoResponse. "Completing this Phase 1 study reflects our ongoing commitment to develop impactful treatments to improve outcomes for cancer patients." The Phase 1 study was designed to determine the safety, tolerability, and preliminary anti-tumor activity of OR502 administered as monotherapy and in combination with anti-PD-1 in subjects with advanced solid tumors. "We are excited by the vast promise of OR502 with preclinical and initial clinical data showing superiority over other anti-LILRB2 antibodies," said Kamal D. Puri, Chief Scientific Officer of OncoResponse. See the full press release in our News Center for more details, and view the poster on the Publications & Presentations page of our website. #OncoResponse #OR502 #EliteCancerResponders

OncoResponse will be presenting two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 39th annual meeting in Houston, TX. Details are as follows: Title (Late-Breaking Abstract):?Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in subjects with advanced cancers? ?????Abstract Number:?1464 ?????Details:?Saturday, November 9th,?George R. Brown Convention Center Title:?Adaptive design elements in a Ph 1-2 study of OR502, a novel antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in response to evolving Ph 1 data and changing regulatory environment ?????Abstract Number:?680 ?????Details:?Saturday, November 9th, George R. Brown Convention Center The posters will be available on our website following their respective sessions. Plan to stop by our posters to talk to members of our team about our research and clinical results. #OncoResponse #OR502 #EliteCancerResponders

Excited to be speaking at the PEGSummit May 13-17 in Boston. I will present data with OncoResponse’s tumor microenvironment modulating antibodies to overcome resistance to immune checkpoint blockade. #OncoResponse, #OR502, #OR641, #MacrophageTherapies, #Immunotherapy, #PEGSummit

CEO Clifford Stocks will be presenting at Life Science Washington's Life Science Innovation Northwest 2024 in Seattle, WA this week. On Day 1 of the conference, Cliff will give a company presentation as part of the Company/Research Institution Presentations on Biotechnology, Immunology & Vaccines, and Oncology. Stop by in-person to hear from Cliff or check out our website for recent updates on OncoResponse. #EliteCancerResponders #LSINW24

Dr. Kamal D. Puri, PhD, will be presenting at and participating in Festival of Biologics 2024 in San Diego, CA from April 15th-17th, 2024. On Day 1 of the conference, he will give an oral presentation titled "Reprogramming human macrophages to relieve immunosuppression in the tumor microenvironment" at 5:10pm PST. On Day 2, he will chair a roundtable session titled "Overcoming the Tumor Microenvironment for Effective Immunotherapy" at 11:30am PST. #EliteCancerResponders #FOB2024

S4 E50 Insights on Leadership: Listen to the full conversation between Clifford Stocks, founder and CEO of OncoResponse and Wyant Simboli principal John Simboli at wyantsimboli.com/bioboss?

CEO Clifford Stocks will be representing OncoResponse at the esteemed J.P. Morgan 42nd Annual Healthcare Conference, taking place this week in San Francisco, CA. We eagerly anticipate the opportunity to engage with the J.P. Morgan investment network, as well as global healthcare industry leaders and valued members of the biotech community. #EliteCancerResponders

OncoResponse is excited to announce the dosing of the first participant in the Phase 1/2 trial of OR502, our novel, best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression. “Initiating this study in cancer patients reflects our continued commitment to advancing programs that have the greatest potential to improve outcomes for patients undergoing cancer treatment,” said?Clifford Stocks, Chief Executive Officer of OncoResponse. See the full release for more information on the study. #EliteCancerResponders